COSCIENS Biopharma Inc.
CSCI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.01 | -0.01 | -0.00 |
| FCF Yield | -41.65% | -28.05% | -41.71% | -67.90% |
| EV / EBITDA | -1.56 | 0.82 | 1.18 | 1.25 |
| Quality | ||||
| ROIC | -10.49% | -14.67% | -27.15% | -17.14% |
| Gross Margin | 35.43% | 29.53% | 61.68% | 44.72% |
| Cash Conversion Ratio | 1.65 | 0.51 | 0.45 | 1.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.41% | -9.56% | -13.01% | -19.79% |
| Free Cash Flow Growth | -80.75% | 24.80% | 58.18% | -411.64% |
| Safety | ||||
| Net Debt / EBITDA | 2.96 | 3.55 | 2.69 | 3.43 |
| Interest Coverage | -102.30 | -51.67 | -286.71 | -286.05 |
| Efficiency | ||||
| Inventory Turnover | 0.97 | 0.43 | 0.47 | 0.28 |
| Cash Conversion Cycle | 105.61 | 77.63 | 87.02 | 186.53 |